<p>尽管大麻行业在美国几乎已经合法化，但并非唯一一种试图突破监管障碍的替代医学形式。像溴酰胺、麦角酸和氯胺酮这样的化合物都被称为致幻剂，然而它们可能具有刚开始被探索的医疗应用。</p>
<p>因此，一些新近上市的公司已经开始尝试利用这些化合物的治疗潜力。当这些公司首次上市时，围绕其项目的兴奋迅速推高了它们的交易价值，随后紧随其后的抛售使大多数公司陷入了显著的低谷。</p>
<p>然而，有几只强劲的致幻股票可以在低谷时购买，以获取潜在的丰厚回报。这是因为几项研究表明，当以正确剂量给药时，LSD、溴酰胺和氯胺酮都非常有效地治疗抑郁症。因此，这些公司可能只是时间问题，它们将迎来他们的辉煌时刻。</p>
<h2>ATAI 生命科学（ATAI）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Shutterstock</p>
<p>作为对替代疗法的更广泛投资，<strong>ATAI 生命科学</strong>（纳斯达克：<strong>ATAI</strong>）目前正在研究基于氯胺酮、伊波甲醚和 N,N-二甲基色胺（DMT）等致幻物质的多种药物。尽管这些化合物可能以娱乐用途而闻名，但已经有几项同行评议的研究开始探索它们治疗心理健康障碍的潜力。</p>
<p>在 ATAI 的情况下，该公司有几种源自溴酰胺、氯胺酮和 DMT 的药物正在研发中，其中最有前途的是 COMP360，作为与另一家制药公司合作的一部分，已进入第三阶段临床试验。这种广泛的治疗方法确实给 ATAI 的运营带来了财务压力，但提高了突破和潜在的美国食品药品监督管理局（FDA）批准的可能性。</p>
<p>因此，ATAI 是在低谷时购买的最佳致幻股票之一，因为它目前以其首次公开发行价格的 93% 折扣交易。任何关于其药物的好消息都可能迅速提振其价值。</p>
<h2>Compass Pathways（CMPS）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Shutterstock</p>
<p>我之前提到 ATAI 正在与另一家公司开发一种名为 COMP360 的药物。那家公司就是 <strong>Compass Pathways</strong>（纳斯达克：<strong>CMPS</strong>），因此名称中有 COMP。这种药物目前是 CMPS 唯一正在开发的项目，这意味着该公司代表了与 ATAI 非常不同类型的制药投资。</p>
<p>因此，投资于 CMPS 意味着致力于治疗中的溴酰胺一侧。通过这种方法，投资者知道直接的催化剂取决于 COMP360 的 FDA 批准。因此，让我们谈谈 COMP360 背后的研究。目前，CMPS 在其网站上提供了其第 IIb 阶段数据表，以供参考其药物的功效。第 IIb 阶段试验专注于对传统抗抑郁化合物抵抗的患者，这意味着选择性 5-羟色胺再摄取抑制剂等药物无效。</p>
<p>在研究的总参与者中，有 20% 报告称在研究第 12 周时持续改善和治疗效果。考虑到这些患者已经对治疗非常抵抗，这是相当令人印象深刻的。因此，像 CMPS 这样的致幻股票可能值得投资。</p>
<h2>Cybin（CYBN）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Shutterstock</p>
<p>正如公司名称所示，<strong>Cybin</strong>（纽交所市场：<strong>CYBN</strong>）专注于开发三种基于溴酰胺的疗法，CYB003、CYB004 和 SPL028，同时还在对其他致幻化合物进行临床前测试。目前，该股票交易价格仅为 26 美分，处于便士股票领域，这可能会让一些投资者感到担忧，但重要的是要记住，该公司的交易历史相当新，其产品仍在争取 FDA 批准。</p>
<p>此外，其溴酰胺治疗，特别是重氘化溴酰胺计划已获得 FDA 授予治疗突破性地位，用于治疗重性抑郁症，其第 II 期试验取得成功。该计划还经过测试，用于治疗酒精滥用障碍，也可能成为该类别的突破性疗法。</p>
<p>对于 Cybin，投资者可能希望等到公司能够产生收入。因为它目前处于增长、研发阶段，该公司过去四个季度仅报告了亏损。</p>
<p>_在发布日期，Viktor Zarev 在本文中提到的证券中没有（直接或间接）任何头寸。本文中表达的观点属于作者本人，受到 InvestorPlace.com 发布指南的约束。</p>
<p>_在发布日期，负责编辑在本文中提到的证券中没有（直接或间接）任何头寸。</p>
<p>Viktor Zarev 是一位科学家、研究员和作家，专门通过对准确性和理解的执着来解释技术股票的复杂世界。</p>

CMPS

CYBN

ATAI

<p>最近，受到影响，一些新上市的致幻药产业公司的交易价值有所下跌。然而，在这种下跌中，有几只强劲的致幻药股票值得考虑购买，包括 ATAI 生命科学（ATAI）、Compass Pathways（CMPS）和 Cybin（CYBN）。这些公司正在进行有关致幻物质潜在医疗应用的研究与开发。ATAI 正在研究基于致幻物质的多种药物，而 CMPS 专注于赛洛西宾疗法的开发。CYBN 专注于开发赛洛西宾疗法，并已获得 FDA 的突破性治疗地位</p>

<p>While the cannabis industry has all but become legitimate in the United States, it’s not the only form of alternative medicine attempting to break through regulatory barriers. Compounds like psilocybin, lysergic acid and ketamine are all referred to as psychedelics, yet they may have medical applications which are just beginning to be explored.</p>
<div class="lb-trans"><p>尽管大麻行业在美国几乎已经合法化，但并非唯一一种试图突破监管障碍的替代医学形式。像溴酰胺、麦角酸和氯胺酮这样的化合物都被称为致幻剂，然而它们可能具有刚开始被探索的医疗应用。</p>
</div><p>As such, several newly minted public companies have begun experimenting with ways to harness the therapeutic potential of these compounds. When these companies first went public, the excitement around their projects quickly spiked their trading value followed by a rapid selloff which put most of them in a significant dip.</p>
<div class="lb-trans"><p>因此，一些新近上市的公司已经开始尝试利用这些化合物的治疗潜力。当这些公司首次上市时，围绕其项目的兴奋迅速推高了它们的交易价值，随后紧随其后的抛售使大多数公司陷入了显著的低谷。</p>
</div><p>Yet there are several strong psychedelic stocks to buy on the dip for potentially lucrative returns. That’s because several studies have shown that LSD, psilocybin and ketamine are all exceptionally effective at treating depression when administered in the correct doses. Thus, it may be just a matter of time before these companies have their moment in the sun.</p>
<div class="lb-trans"><p>然而，有几只强劲的致幻股票可以在低谷时购买，以获取潜在的丰厚回报。这是因为几项研究表明，当以正确剂量给药时，LSD、溴酰胺和氯胺酮都非常有效地治疗抑郁症。因此，这些公司可能只是时间问题，它们将迎来他们的辉煌时刻。</p>
</div><h2>Atai Life Sciences (ATAI)</h2>
<div class="lb-trans"><h2>ATAI 生命科学（ATAI）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Shutterstock</p>
<div class="lb-trans"><p>来源：Shutterstock</p>
</div><p>A broader play into alternative therapies, <strong>Atai Life Sciences</strong> (NASDAQ: <strong>ATAI</strong>) is currently researching multiple drugs based on psychedelic substances like ketamine, ibogaine and N,N-dimethyltryptamine (DMT). These compounds, while perhaps known for their recreational use have seen several peer-reviewed studies begin to explore their potential for treating mental health disorders.</p>
<div class="lb-trans"><p>作为对替代疗法的更广泛投资，<strong>ATAI 生命科学</strong>（纳斯达克：<strong>ATAI</strong>）目前正在研究基于氯胺酮、伊波甲醚和 N,N-二甲基色胺（DMT）等致幻物质的多种药物。尽管这些化合物可能以娱乐用途而闻名，但已经有几项同行评议的研究开始探索它们治疗心理健康障碍的潜力。</p>
</div><p>In the case of ATAI, the company has several drugs derived from psilocybin, ketamine and DMT in the pipeline, with itsmost promising one COMP360, entering Phase 3 clinical trials as part of a co-development with another pharmaceutical company. This wide approach to developing treatment does put a financial strain on ATAI’s operations, but it improves the likelihood of a breakthrough and potential Food and Drug Administration (FDA) approval.</p>
<div class="lb-trans"><p>在 ATAI 的情况下，该公司有几种源自溴酰胺、氯胺酮和 DMT 的药物正在研发中，其中最有前途的是 COMP360，作为与另一家制药公司合作的一部分，已进入第三阶段临床试验。这种广泛的治疗方法确实给 ATAI 的运营带来了财务压力，但提高了突破和潜在的美国食品药品监督管理局（FDA）批准的可能性。</p>
</div><p>As such, ATAI is one of the best psychedelic stocks to buy on the dip, as it currently trades at a 93% discount on its initial public offering price. Any good news regarding one of its drugs could bolster its value rapidly.</p>
<div class="lb-trans"><p>因此，ATAI 是在低谷时购买的最佳致幻股票之一，因为它目前以其首次公开发行价格的 93% 折扣交易。任何关于其药物的好消息都可能迅速提振其价值。</p>
</div><h2>Compass Pathways (CMPS)</h2>
<div class="lb-trans"><h2>Compass Pathways（CMPS）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Shutterstock</p>
<div class="lb-trans"><p>来源：Shutterstock</p>
</div><p>I mentioned earlier that ATAI is developing a drug called COMP360 with another company.That company is <strong>Compass Pathways</strong> (NASDAQ: <strong>CMPS</strong>), hence the COMP in the name. This drug is currently the only project in development for CMPS, which means the company represents a very different type of pharmaceutical investment than ATAI.</p>
<div class="lb-trans"><p>我之前提到 ATAI 正在与另一家公司开发一种名为 COMP360 的药物。那家公司就是 <strong>Compass Pathways</strong>（纳斯达克：<strong>CMPS</strong>），因此名称中有 COMP。这种药物目前是 CMPS 唯一正在开发的项目，这意味着该公司代表了与 ATAI 非常不同类型的制药投资。</p>
</div><p>As such, investing in CMPS means committing to the psilocybin side of therapeutics. With this approach, investors know the direct catalyst relies on FDA approval for COMP360. So let’s talk about the studies behind COMP360. Currently, CMPS offers its Phase IIb datasheet on its site for reference on its drug’s efficacy. The Phase IIb trial focused specifically on patients with depression who were resistant to traditional anti-depressant compounds, meaning drugs like selective serotonin reuptake inhibitors were ineffective.</p>
<div class="lb-trans"><p>因此，投资于 CMPS 意味着致力于治疗中的溴酰胺一侧。通过这种方法，投资者知道直接的催化剂取决于 COMP360 的 FDA 批准。因此，让我们谈谈 COMP360 背后的研究。目前，CMPS 在其网站上提供了其第 IIb 阶段数据表，以供参考其药物的功效。第 IIb 阶段试验专注于对传统抗抑郁化合物抵抗的患者，这意味着选择性 5-羟色胺再摄取抑制剂等药物无效。</p>
</div><p>Of the total participants in the study, 20% reported sustained improvement and therapeutic effects by the 12th week of the study. When you consider that these patients were already exceptionally resistant to treatment, that’s quite impressive. Thus, COMP360 could be worth investing in through psychedelic stocks to buy on the dip such as CMPS.</p>
<div class="lb-trans"><p>在研究的总参与者中，有 20% 报告称在研究第 12 周时持续改善和治疗效果。考虑到这些患者已经对治疗非常抵抗，这是相当令人印象深刻的。因此，像 CMPS 这样的致幻股票可能值得投资。</p>
</div><h2>Cybin (CYBN)</h2>
<div class="lb-trans"><h2>Cybin（CYBN）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Shutterstock</p>
<div class="lb-trans"><p>来源：Shutterstock</p>
</div><p>As the name of the company suggests, <strong>Cybin</strong>(NYSEMKT: <strong>CYBN</strong>) specializes in developing three psilocybin-based therapies, CYB003, CYB004, and SPL028, with other psychedelic compounds in preclinical testing. Currently, the stock trades in penny stock territory at just 26 cents a share, which may concern some investors, but it is important to remember that the trading history of the company is fairly new and its products are still vying for FDA approval.</p>
<div class="lb-trans"><p>正如公司名称所示，<strong>Cybin</strong>（纽交所市场：<strong>CYBN</strong>）专注于开发三种基于溴酰胺的疗法，CYB003、CYB004 和 SPL028，同时还在对其他致幻化合物进行临床前测试。目前，该股票交易价格仅为 26 美分，处于便士股票领域，这可能会让一些投资者感到担忧，但重要的是要记住，该公司的交易历史相当新，其产品仍在争取 FDA 批准。</p>
</div><p>Moreover, its psilocybin treatment, specifically the Deuterated Psilocybin Program has been granted breakthrough treatment status by the FDA for treating major depressive disorder following its Phase II trial success. This program has also been tested for treating alcohol abuse disorders and could be a breakthrough therapy for that category as well.</p>
<div class="lb-trans"><p>此外，其溴酰胺治疗，特别是重氘化溴酰胺计划已获得 FDA 授予治疗突破性地位，用于治疗重性抑郁症，其第 II 期试验取得成功。该计划还经过测试，用于治疗酒精滥用障碍，也可能成为该类别的突破性疗法。</p>
</div><p>In the case of Cybin, investors may want to wait until the company can generate revenue, however. Because it is currently in a growth, research and development phase, the company has only reported losses for the last four quarters.</p>
<div class="lb-trans"><p>对于 Cybin，投资者可能希望等到公司能够产生收入。因为它目前处于增长、研发阶段，该公司过去四个季度仅报告了亏损。</p>
</div><p><em>On the date of publication, Viktor Zarev did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.</em></p>
<div class="lb-trans"><p>_在发布日期，Viktor Zarev 在本文中提到的证券中没有（直接或间接）任何头寸。本文中表达的观点属于作者本人，受到 InvestorPlace.com 发布指南的约束。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p>_在发布日期，负责编辑在本文中提到的证券中没有（直接或间接）任何头寸。</p>
</div><p>Viktor Zarev is a scientist, researcher, and writer specializing in explaining the complex world of technology stocks through dedication to accuracy and understanding.</p>
<div class="lb-trans"><p>Viktor Zarev 是一位科学家、研究员和作家，专门通过对准确性和理解的执着来解释技术股票的复杂世界。</p>
</div>

2024 年夏季值得抄底的 3 只迷幻药股票